LLAI vs. PRM, GDR, ABDX, GENI, VRCI, AGL, BVX, IMM, MXC, and TLY
Should you be buying LungLife AI stock or one of its competitors? The main competitors of LungLife AI include Proteome Sciences (PRM), genedrive (GDR), Abingdon Health (ABDX), GENinCode (GENI), Verici Dx (VRCI), ANGLE (AGL), BiVictriX Therapeutics (BVX), ImmuPharma (IMM), Argent BioPharma (MXC), and Totally (TLY). These companies are all part of the "medical" sector.
LungLife AI (LON:LLAI) and Proteome Sciences (LON:PRM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.
42.2% of LungLife AI shares are owned by institutional investors. Comparatively, 23.0% of Proteome Sciences shares are owned by institutional investors. 48.7% of LungLife AI shares are owned by insiders. Comparatively, 21.2% of Proteome Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Proteome Sciences has higher revenue and earnings than LungLife AI.
LungLife AI has a beta of -0.2, indicating that its stock price is 120% less volatile than the S&P 500. Comparatively, Proteome Sciences has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500.
In the previous week, Proteome Sciences had 1 more articles in the media than LungLife AI. MarketBeat recorded 1 mentions for Proteome Sciences and 0 mentions for LungLife AI. Proteome Sciences' average media sentiment score of 1.03 beat LungLife AI's score of 0.00 indicating that Proteome Sciences is being referred to more favorably in the news media.
Proteome Sciences received 162 more outperform votes than LungLife AI when rated by MarketBeat users.
Proteome Sciences has a net margin of 8.83% compared to LungLife AI's net margin of 0.00%. Proteome Sciences' return on equity of 0.00% beat LungLife AI's return on equity.
Summary
Proteome Sciences beats LungLife AI on 10 of the 13 factors compared between the two stocks.
Get LungLife AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for LLAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LungLife AI Competitors List
Related Companies and Tools
